Cascadian Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference
February 27 2017 - 09:00AM
Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage
biopharmaceutical company, today announced that management will
present at the Cowen and Company 37th Annual Health Care Conference
on Monday, March 6, 2017, at 3:20 p.m. Eastern time / 12:20 p.m.
Pacific time in Boston.
A live audio webcast of the presentation will be available
through the “Events & Presentations” page of the “News &
Events” section of Cascadian Therapeutics’ website at
cascadianrx.com. An archived edition of the session will be
available later that day.
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical
company dedicated to developing innovative product candidates for
the treatment of cancer. The lead product candidate, tucatinib
(also known as ONT-380) is an oral, selective small molecule HER2
inhibitor. Cascadian Therapeutics is conducting a randomized,
double-blind controlled pivotal clinical trial
called HER2CLIMB, which is comparing tucatinib vs. placebo in
combination with capecitabine and trastuzumab in patients with
locally advanced or metastatic HER2-positive breast cancer with and
without brain metastases, who have previously been treated with a
taxane, trastuzumab, pertuzumab and T-DM1. Additional details
on HER2CLIMB can be found at www.clinicaltrials.gov (Identifier:
NCT02614794) or www.HER2CLIMB.com. For more information, please
visit www.cascadianrx.com.
Investor and Media Contact:
Monique Greer
Cascadian Therapeutics
206-801-2107
mgreer@cascadianrx.com
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Mar 2023 to Mar 2024